| abstract |
FIELD: biotechnology. n SUBSTANCE: invention relates to biotechnology, specifically recombinant cell CYTO-CAR-YT-Lact, exhibiting high cytotoxic activity with respect to PSMA-positive human cancer cells. Line is produced in two stages: first, a YT cell line is transduced by lentiviral particles coding a chimeric antigenic receptor against PSMA protein and a recombinant lactaptin peptide, and then performing produced CAR-YT-Lact line transduction by lentiviral particles pre-processed using recombinant lentiviral plasmids lentiCRISPRv2-Shp2g1 and lentiCRISPRv2-Shp2g2, characterized in accordance with physical maps presented in fig. 1 and fig. 3, following features: have size of 13012 base pairs, encoding main functional-structural elements of the CRISPR/Cas9 system and consisting of the following elements: a human snRNA U6 promoter; sgRNA to third and fifth exons of PTPN11 gene, respectively; human promoter EF1a; chimeric protein composition Cas9-NLS-FLAG-P2A-PURO. n EFFECT: invention increases cytotoxic activity in relation to PSMA-positive human cancer cells. n 1 cl, 8 dwg, 6 ex |